Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors’ reply.

Flint A, Andersen G, Hockings P, Plum-Mörschel L, Loomba R. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1498. doi: 10.1111/apt.16669.